Decheng Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Decheng Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-181,600	Closed	-$1.3M	–	21
2025 Q3	$1.3M	Hold	181,600	–	–	0.23%	17
2025 Q2	$8.57M	Buy	181,600 +10,000	+6%	+$407K	2.16%	9
2025 Q1	$6.7M	Hold	171,600	–	–	1.88%	10
2024 Q4	$9.29M	Buy	171,600 +5,000	+3%	+$255K	1.99%	9
2024 Q3	$8.4M	Hold	166,600	–	–	1.99%	11
2024 Q2	$7.33M	Hold	166,600	–	–	2.24%	11
2024 Q1	$8.37M	Buy	+166,600	New	+$9.04M	1.12%	11

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Decheng Capital's MLTX Position: Q4 2025 in Review

Decheng Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 181,600 shares — an estimated $1.3M sold.

Decheng Capital first reported a position in MLTX in Q1 2024 and held it in 7 quarters. The position peaked at $9.29M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Decheng Capital reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Decheng Capital sold 181,600 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $1.3M.
Decheng Capital first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 7 quarters.
Decheng Capital's MoonLake Immunotherapeutics position peaked at $9.29M in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Decheng Capital's 13F filing for Q4 2025, filed 12 Feb 2026.